(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said CAHtalyst Pediatric and Adult Phase 3 Studies of Crinecerfont in congenital adrenal hyperplasia (CAH) met primary goals. Congenital adrenal ...
The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received FDA Orphan Drug and ...
In 2025, hospitals and health systems have said they are focused on two things: financial stability and patient experience. In a LinkedIn poll, Becker’s asked: Which of these will rank highest among ...
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results